Filing Flows › BillionToOne (BLLN) › Q2 2026 › vs Q1 2026
BillionToOne (BLLN) Q2 2026 vs Q1 2026 (quarter over quarter)
BillionToOne's revenue rose $1.1M (+1%) from $108M in Q1 2026 to $109M in Q2 2026. The biggest changes: Oncology +$2.9M (+27%); Prenatal −$2.3M (-2%); Clinical trial support and other services +$394K (+34%). Gross margin 70.5% against 73.0% (-2.5 pts).
BillionToOne, Q2 2026: revenue $109M (+64% year over year), operating margin 5.0%, net earnings $8.1M, operating cash flow $9.1M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 70.5% | 73.0% | -2.5 pts |
| Operating margin | 5.0% | 16.5% | -11.4 pts |
| Net margin | 7.4% | 16.6% | -9.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Prenatal | $94.2M | $96.5M | −$2.3M | -2% |
| Oncology | $13.7M | $10.7M | $2.9M | +27% |
| Clinical trial support and other services | $1.5M | $1.1M | $394K | +34% |
| Revenue | $109M | $108M | $1.1M | +1% |
| Gross profit | $77.1M | $79.1M | −$2.0M | -3% |
| Cost of revenue | $32.3M | $29.3M | $3.0M | +10% |
| Other income, net | $2.0M | $675K | $1.3M | +199% |
| Operating profit | $5.5M | $17.8M | −$12.3M | -69% |
| Operating expenses | $71.6M | $61.3M | $10.3M | +17% |
| Pre-tax earnings | $7.5M | $18.5M | −$11.0M | -59% |
| Research & development | $17.3M | $14.7M | $2.6M | +18% |
| SG&A | $54.3M | $46.6M | $7.7M | +17% |
| Income tax benefit | $536K | −$539K | $1.1M | — |
| Net earnings | $8.1M | $18.0M | −$9.9M | -55% |
| Operating cash sources | $18.1M | $26.2M | −$8.1M | -31% |
| Depreciation & amortization | $1.8M | $1.7M | $91K | +5% |
| Share-based compensation | $8.2M | $6.5M | $1.7M | +26% |
| Working capital & other | $9.0M | $10.8M | −$1.8M | -17% |
| Operating cash flow | $9.1M | $15.4M | −$6.3M | -41% |
Questions
How much did BillionToOne's revenue grow quarter over quarter in Q2 2026?
BillionToOne's revenue rose $1.1M (+1%) from $108M in Q1 2026 to $109M in Q2 2026.
What drove BillionToOne's revenue change in Q2 2026?
Oncology +$2.9M (+27%); Prenatal −$2.3M (-2%); Clinical trial support and other services +$394K (+34%).